海外直播b站

Dr. Esfahani's research focus is on the study of immune checkpoint inhibitors (ICI). These inhibitors are among the most promising approaches to fight cancer. The use of these agents that enhance the host鈥檚 immune system to fight tumors has led to astounding outcomes in previously refractory cancers. The enhancement of immunity with ICI is also responsible for serious, undesirable off-target immune and inflammatory events known as immune-related adverse events (irAE). Although some can be transient, others require immunosuppressive therapy and discontinuation of ICI. Dr. Esfahani's聽vision is to identify mechanisms driving irAE with the hope of designing mitigation strategies that would allow for a safer and more targeted delivery of ICI